4:30 PM
 | 
Jun 22, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Affiris' Affitope PD03A well tolerated in Phase I to treat early PD

Affiris AG (Vienna, Austria) reported top-line data from a single-blind, placebo-controlled, Austrian Phase I AFF011 trial in 36 patients with early Parkinson’s disease (PD) showing that 15 and 75 µg doses of subcutaneous Affitope PD03A were well tolerated with no treatment-related serious adverse events reported. Local reactions comprised about 59%...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >